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TUMOUR necrosis factor-a (TNF-) was measured Tumour necrosis factor- in nasal
by enzyme-linked immunosorbent assay and
eostnoph cationic protein (ECP) by radio- allergy
immunoassay to evaluate TNF- in nasal all.
There was no significant difference either
between the mean concentrations of TNF-a in K. Hisamatsu,’ T. Ganbo, T. Nakazawa, nasal secretions from the patients with perennial T. Nakajima, J. Ko, R. Goto, g. Murakami and nasal allergy and those of normal subjects, or
between the TNF-a and ECP concentrations. K. Misui
2
However, reverse transcription polymerase chain
reaction showed a specific increase of TNF-a
mRNA and IFN-7 mRNA in allergic nasal mucosa 1Department of Otorhinolaryngology and 2Second
after allergen challenge in vitro. These findings Department of Biochemistry, Yamanashi Medical
suggest a possibility that T cell-derived IFN-/ University, 1110 Shimokato, Tamaho-cho, up-regulates macrophages to elaborate TNF-,
which may play a role in amplifying allergic Nakakoma-gun, Yamanashi-ken 409-38, Japan
inflammation in the nose through the cytokine
network.
Key words: ECP, IFN-7, mRNA, NIH image, rhinitis, RT-
PCR, TNF-0t.
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Introduction we measured eosinophil cationic protein (ECP)
in nasal secretions.
Tumour necrosis factor<z (TNF-cz)was identi-
fied as an anti-tumour cytokine derived from
macrophages (M). So far, the sources of TNF- Materials and Methods
0t include M(, activated T cells,
2 and mast
cells.3’4 TNF-0t has been recognized as having Subjects: We studied 27 patients (15 males and
various biological activities relevant to inflamma- 12 females, ranging in age from 21 to 32 years)
tion, such as expressing adhesion molecules on and eight normal volunteers (four males and
endothelium,
5 being chemoattractant,
6 and four females, ranging from 23 to 31 years).
enhancing microvascular permeability] Recently, Patients were diagnosed with perennial nasal
an increase of TNF-0t in bronchoalveoral lavage allergy according to the following criteria: (1)
fluids has been reported and recognized as an perennially persistent and recurrent nasal syrup-
important mediator in bronchial asthma.
8 toms consisting of sneezing attacks, watery nasal
However, there have not been sufficient studies discharge and nasal obstruction; (2) positive
to clarify the role of TNF-0t in nasal allergy. It eosinophilia in nasal smear test; and (3) house
has been reported that T cells elaborate inter- dust-positive intradermal reaction and/or IgE
feron-7 (IFN-7) to activate M.
9 Furthermore, antibody against house dust mite, Dermatopba-
recently, we elucidated the accumulation of acti- goides farine in the serum. All patients and
vated helper T cells in the nasal mucosa of normal subjects gave informed consent. None of
allergy patients by measuring soluble interleukin- the patients or controls had other inflammatory
2 receptor (sIL-2R). These reports further diseases and none received any medication
suggest that T cells may induce TNF-z elabora- prior to nasal lavage collection. For mRNA analy-
tion by M and mast cells in allergic nasal sis, the nasal mucosa obtained at surgery from
mucosa through the cytokine network following four patients with house dust mite allergy was
allergen exposure, used.
To investigate TNF<z in nasal allergy in the
present study, we measured TNF-z in the nasal Assessment of clinical severity of nasal allergy.
secretions of allergic patients. We also investi- Nasal symptoms scored in a symptom diary were
gated TNF-z mRNA and IFN-7 mRNA in the assessed and the clinical severity was determined
nasal mucosa using reverse transcription poly- according to Okuda’s criterion.
1 Frequency of
merase chain reaction (RT-PCR) after allergen sneezing attacks, nose blowing and patient-asses-
challenge in vitro. Furthermore, to investigate sed grade of nasal obstruction were scored, and
the relationship between TNF-a and eosinophils, symptom grades were determined as mild, rood-
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erate or severe. When one or more of these 2001.tl of TNF-cz conjugate was added after
symptoms were severe, overall clinical severity washing three times, then incubated for 1 h at
was considered severe. When the symptoms were room temperature. Then 200 tl of substrate solu-
moderate or mild, overall severity was considered tion was added after washing three times, and
moderate. When all of three symptoms were incubated for 2 min at room temperature, fol-
mild, overall severity was considered mild. lowed by adding 50tl of stop solution. The
absorbance was measured at 450nm using an
Nasal smear tes Nasal smears were obtained automatic spectrophotometer (Titerteck Multi-
prior to nasal lavage, and cytologically investi- scan(R) PLUS MKII, Flow Laboratories Inc., CA,
gated using Hansel’s staining procedure
2 and USA). The absorbance of samples was measured
nasal cytograms were graded according to a by the spectrophotometer after calibrating the
semi-quantitative scale as reported previously.3 equipment to 0 using the substrate blank. TNF-0t
concentration in the nasal secretion was calcu-
Preparation for measurement of TNF<z, and lated according to the above equation. The
ECP: Nasal lavage fluids were obtained by minimal detectable dose using a standard curve
washing with 20ml of 0.9% saline solution con- was 4.4 pg/ml.
taining ImM LiC1, pre-warmed to 37C, using a
30ml plastic syringe with minimal stimulation of Measurement of ECP: The nasal lavage fluids
the nasal mucosa. The total volume of recovered from 18 allergic patients and from eight normal
lavage fluid was measured and the nasal lavage subjects were radioimmunoassayed (Pharmacia
fluid was centrifuged twice at 1350 x g for 10 ECP RIA kit(R), Pharmacia Diagnostics AB,
min at 4C. Sputolysin
(R) (Behring Diagnostics La Uppsala, Sweden) to determine ECP concentra-
Jolla, CA, USA)was mixed with nasal lavage fluid tions as described elsewhere.5 The minimal
at a volume ratio of 0.4/9.0, and immediately detectable ECP was 2 pg/ml.
shaken for 1 min, and then 5.5% aprotinin
(Sigma, MO, USA) was added at a volume ratio Reverse transcription polymerase chain reaction:
of 0.1/9.4, followed by immediate mixing for 1
min at room temperature. The fluid was allowed Preparation of the nasal mucosa for RT-PCR.
to stand for 30 minutes at room temperature, Mucosal specimens were obtained from the
then centrifuged twice at 1350 x g for 10 min at inferior turbinates of allergic patients at times of
4C and stored at -80C until TNF-cz and ECP surgery. The specimens were cut into
were assayed. 4mm x 4mm pieces, and incubated with or
The lithium (Li) concentration in the nasal without extract of Dermatophagoidesfarine at a
lavage was measured by atomic emission spec- concentration of 1 btg/ml for 15 min in RPMI
trophotometry to calculate TNF-0t and ECP con- I640, and then incubated at 37C for 3 h.
centrations in the nasal secretions. Li was used as
an exogenous marker of nasal secretion allowing Extraction of RNA. RNA was extracted from the
calculations to be made from small amounts of mucosal specimens using RNeasyTM kit (QIAGEN,
nasal secretion.
4 The TNF<z concentration (TNF- CA, USA). After treatment with DNase (Promega,
x) was calculated by the following equation: WI, USA) at a ratio of 1 unit/tg RNA, to clean up
the RNA, the RNA product was treated with the
TNF-czx TNF-Zn x Lio/(Lio tin) RNeasyTM kit (QIAGEN, ca, USA).
where TNF-CZn denotes the TNF-cz concentration Preparation of cDNA. The RNA was incubated at
of the sample; Lio, the Li concentration of the 65C for 10 min. One tg of the RNA, 2 !1 of 10
0.9% NaC1 for lavage; and Lin, the Li concentra- x PCR Buffer II, 2 l.tl of 25mM MgCl2 (Perkin-
tion of the sample. The ECP concentrations were Elmer, NJ, USA), 411 of 2.5mM d-NTPs (dATP,
calculated by the same equation using ECP dCTP, dGTP and dTTP; Pharrnacia, NJ, USA), l btl
instead of TNF-cz. of 20 U/l.tl RNasin (Wako, Osaka, Japan), 1 !,1 of
100pM random primer, 1 !1 of 200 unit/l.tl of Mo-
Measurement of TNF<z by enzyme-linked immu- MLVReverse Transcriptase (Gibco BRL, NY, USA)
nosorbent assay: Enzyme-linked immunosorbent were mixed and adjusted to 20 I1 in total volume
Tt assay (Quantikine R&D Systems, Inc. MN, by adding DEPC-water. The reaction mixture
USA) was used to detect TNF<z in nasal lavage was allowed to stand at room temperature for 10
fluids. The assay was performed in duplicate, min, then incubated at 42C for 60 min, and at
Briefly, 200 btl of standard or sample was added 95C for 5 min in a water bath. The obtained
to 50 tl of the diluent and incubated at 37C for reverse transcription solution (cDNA) was stored
2h in a fiat-bottomed 96-well microplate. Then at-20C.
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Table 1. Sequences of primers used in RT-PCR
Target genes 5’ primers 3’ primers Size of PCR product, bp
I[}-actin
TNF-
INF-7
5’-ATGGATGATGATATCGCC-3’
5’-CTGCTGCACTTTGGAGTGAT-3’
5’-AATGCAGGTCATTCAGATG-3’
5’-ATGAGGTAGTCAGTCAGGT-3’
5’-CCTTGGTCTGGTAGGAGACG-3’
5’-CTGGGATGCTCTTCGACCTC-3’
574
356
386
PCR. The mixture consisted of 2 l.tl of cDNA,
2.5 l.tl of 10 x PCR Buffer II, 3 l.tl of 25mM MgC12,
2 I.tl of 2.5mM dNTPs, 12.75 I.tl of DEPC-water,
1.25 rtl of 20 pM 5’-primer and 1.25 btl of 20 btM
Y-primer (Table 1), 0.25 pl of AmpliTaqDNA
polymerase (Perkin-Elmer, NJ, USA) were incu-
bated in the Gene Amp(R)PCR System 2400
(Perkin-Elmer, NJ, USA) at 94C for 30 s, at 55C
for 30 s, at 72C for 1 min with 32 cycles of PCR.
Finally, the PCR mixture was incubated at 72C
for 10 min. The PCR product was stained with
ethidium bromide, and electrophoresis was per-
formed on 1.2% agarose and the gel photo-
graphed. The optical density of each band on the
gel was analysed using an Epson TG-6000, a
Macintosh Ilci computer and a public domain
NIH Image 1.52 program*. There was a linear
relationship between the optical density (OD)
and PCR cycles up to 35 cycles. The ratio of the
OD of each mRNA/the OD of [3-actin mRN.A was
determined to assess changes in mRNA expres-
sions.
Statistical analysis: The Kruskal-Wallis test was
used to evaluate the relationship between TNF-cz
values and clinical severity. To evaluate the differ-
ences between mean values of the two groups,
Student’s t-test was used. Significance was indi-
cated atp < 0.05.
Results
TNF<z concentration in nasal secretions: TNF-0t
was detected in nasal secretions from allergic
patients (n 27) and normal subjects (n 8).
The mean (_ S.E.)values of TNF-a concentra-
tion in nasal secretions from allergic patients and
normal subjects were 489.5 _+ 118.6pg/ml and
269.8 62.4pg/ml, respectively. There was no
significant difference between the mean values of
these two groups, although the mean concentra-
*The program is written by Wayne Rasband at the US
National Institutes of Health and is available on the
Internet by anonymous ftp from zippy.nimh.nih.gov or
on floppy disk from NTIS, 5285 Port Royal Rd, Spring-
field, VA 22161, USA; part number PB93-504868.
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FIG. 1. Correlation between TNF- in nasal secretions and clinical
severity. There was no correlation between TNF- in nasal secre-
tions and clinical severity in perennial nasal allergy patients,
although the mean concentration in mild nasal allergic patients
was significantly higher than that in normal subjects (p < 0.05).
tion of TNF-t of patients with mild nasal allergy
showed a significantly higher level than that of
normal subjects (p < 0.05). There was no corre-
lation between TNF-cz concentration and clinical
severity (Fig. 1).
ECP in nasal secretions: The mean (+_ S.E.)
value of ECP concentration in the nasal secre-
tions of allergic patients was 270.1 Jr 68.51.tg/1
(n-- 19), and it was significantly higher than that
of normal subjects (less than the minimal detec-
tion level of the assay, n=8, p<0.01).
However, there was no correlation between ECP
and TNF-cz concentrations in the same nasal
secretions (r 0.089, Fig. 2).
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FIG. 2. Comparison between TNF- and ECP concentrations in
nasal secretions. There was no correlation between TNF- and
ECP concentrations in nasal secretions.TNFx in nasal allergy
Table 2. The ratios of the OD of mRNAs/the OD of -actin mRNA in the nasal mucosa. The ratios of theOD of
mRNAs of TNF- and IFN-7/that of -actin showed significant differences from the controls 3 h after allergen
challenge, although the base line values of neither mRNA showed any significant differences between the
groups with and without allergen challenge (n=4). There were decreases in the OD ratios of IFN-? and
controls after allergen challenge because of increased OD of -actin mRNA.
Baseline After 3 h
mean -!- S.E. mean -t- S.E.
TNF- mRNA control 0.183 ___
0.016 NS 0.129 -t- 0.032
allergen challenge 0.214 ___
0.001 0.343 -I- 0.045 P < 0.01
control 0.206 ___
0.063 0.116 ___
0.024 IFNq, mRNA allergen challenge 0.292 -I- 0.097 NS 0.262 0.048 P < 0.05
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FIG. 3. Effect of allergen challenge on TNF- mRNA and IFN-7
mRNA in the nasal mucosa. The TNF- mRNA and IFN- mRNA
were increased in the nasal mucosa by specific allergen chal-
lenge in vitro. The figure shows expression of TNF- mRNA and
IFN-y mRNA in allergic nasal mucosa after 3 h incubation follow-
ing challenge with Derrnatophagoides farine extract. Lane M,
DNA molecular weight marker; Lane 1, actin (without allergen
challenge); Lane 2, actin (with allergen challenge); Lane 3,
TNF- (control); Lane 4, TNF- (with allergen challenge); Lane 5,
IFN- (control); Lane 6, IFN-y (with allergen challenge). Ratios of
the OD of TNF- mRNA/the OD of actin mRNA and the OD of
IFN-y mRNA/the OD of -actin mRNA were increased.
Effect of allergen challenge on TNF<z mRNA and
IFN-2 mRNA in the nasal mucosa: RT-PCR
revealed mRNAs of both TNF-cz and IFN-, in the
nasal mucosa. The levels of TNF-z mRNA and
IFN-T mRNA 3 h after allergen challenge in vitro
were significantly higher than those without aller-
gen challenge, although there was no significant
difference between the base line levels of either
mRNA with allergen challenge and those of the
controls (n 4, Table 2, Fig. 3).
Discussion
Specific reaction of the allergen with IgE anti-
bodies bound to mast cells causes immediate
and late nasal responses. The mast cells release
chemical mediators and also elaborate cytokines
such as IL-3,16 IL-4, IL-5, IL-6, GM-CSF
17 and TNF-
oz. These cytokines may take part in the
network and modulate allergic inflammation of
the nasal mucosa.
Eosinophil accumulation in the nasal mucosa
is a hallmark of nasal allergy, and nonspecific
hyperresponsiveness of the nasal mucosa is an
important clinical feature of nasal allergy. Eosino-
phils predominantly release lipid mediators such
as leukotriene C4 (EWe4)19 and platelet activating
factor (PAF)
2 as well as cytotoxic granule pro-
teins such as major basic protein, ECP, eosino-
phil peroxidase and eosinophil derived
neurotoxin.
21 Recent studies have suggested that
eosinophils play an important role in the
mechanism of mucosal nonspecific hyperrespon-
siveness. Therefore, eosinophil recruitment in the
nasal mucosa is crucial in the pathogenesis of
nasal allergy.
In the present study, TNF-cz was detected in
nasal lavage fluid from patients with perennial
nasal allergy. Bachert et a/.22 reported that TNF-z
increased in nasal lavage during immediate nasal
response. Some previous studies have reported
that this cytokine was detected or not detected in
nasal lavages from nasal allergy patients.23’24
Inconsistent results are presumably due to rapid
metabolism of this cytokine in the nasal lavage
fluids and/or the small amount present, so that
the level was undetectable in some cases by
ELISA. It is also surmised that TNF<z might be
converted rapidly during transfer into the nasal
secretions from the nasal mucosa following the
allergic response. We used a protease inhibitor,
aprotinin, in the nasal lavage fluid and this possi-
bly resulted in a successful detection of TNF-z in
the nasal lavage in the present study, although
the level of TNF-cz in nasal secretions did not
show any relation either to clinical severity, or to
the ECP level in nasal secretions. On the other
hand, the ECP level in nasal secretions showed a
positive relationship to clinical severity in our
previous study.
5 Recently, human mast cells
were found to contain preformed TNF-cz which is
capable of release by immunological activa-
tion.3’4’23 These data suggest that TNF-cz may be
released and play a role in immediate nasal
response.
TNF-cz was reported to be derived from acti-
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vated M. To date, it has been reported that not
onlyM but also mast cells and T cells generate
TNF<z, which has various biological activities
such as promotion of: (1) oxygen radical pro-
duction of eosinophils and neutroohils;v (2) mast
cell and eosinophil cytotoxicity;2’26 (3) micro-
vascular permeability;v (4) leukotriene B4 (LTB4)
and PAF generation from eosinophils and neu-
trophils;2v’2. and (5) eosinophil and neutrophil
adhesion to the endothelium and also airway epi-
thelium by expression of adhesion molecules.5’29
Furthermore, it is a chemoattractant for neu-
trophils and monocytes. These biological activ-
ities lead to a hypothesis that TNF-a may amplify
allergic inflammation resulting in mucosal hyper-
responsiveness. Reports that TNF-a induces
airway hyperresponsiveness in experimental
animals’--support this hypothesis.
It has been reported that TNF<z induces
expression of adhesion molecules such as ICAM-
1, VCAM-1 and ELAM-1 on vascular endothelial
cells,29’32’33’34 which may result in the adhesion
of inflammatory cells to the endothelium and
transmigration into the lesion. It is well known
that LTB4 and PAF are potent chemoattractants
for eosinophils5’ despite the fact that these
lipid mediators do not specifically act on eosino-
phils like IL-5.v Therefore, TNF-z might directly
or indirectly be involved in late nasal response
with infiltration of eosinophils and/or other
inflammatory cells in allergic nasal mucosa by
promoting the generation of these lipid media-
tors of inflammatory cells. Thus, to clarifi7
whether TNF<z is generated or not after allergen
challenge, the TNF<z mRNA in the allergic nasal
mucosa was examined using specific RT-PCR
because of presumable small amount of TNF-z
in the culture supernatant.
Specific RT-PCR revealed TNF<z mRNA in the
allergic nasal mucosa before and after allergen
challenge in vitro in the present study. TNF<z
mRNA specifically increased in the allergic nasal
mucosa after allergen challenge. These data
suggest that allergen exposure positively induces
TNF<z generation in allergic nasal mucosa result-
ing in inflammatory cell recruitment. This
hypothesis is supported by positive hybridization
signals for TNF-0t mRNA and a significant
increase in the number of TNF-0t mRNA-positive
cells in the nasal mucosa of allergic patients after
nasal allergen challenge.
The present study also revealed that TNF-z
concentrations in nasal secretions did not corre-
late with either clinical severity or concentrations
of ECP in the nasal secretions obtained from
allergic patients. As previously described, TNF-z
has various biological activities relevant to accu-
mulation and activation of inflammatory cells
involved in allergic reactions. Consequently, these
negative correlations suggest that TNF<z may
indirectly play a role in causing clinical symp-
toms, and other factors may collaborate with
TNF<z in eosinophil activation. In other words,
TNF<z may play a central role in the cytokine
network in the nasal allergy by regulating inflam-
matory cells such as lymphocytes, macrophages,
mast cells and eosinophils.
Our previous studies suggested activation of
helper T cells in nasal allergy by elevation of
slL-2R level in nasal secretions and also cluster
formation of CD25 + cells in the allergic nasal
mucosa. Activated T cells are capable of generat-
ing IFN-7, which is a M activating factor that
promotes TNF-z and IL-1 production of M(.
39
IFN-7 also promotes TNF action by increasing
TNF receptor expression on sensitive cells.4 In
the present study, IFN-7 mRNA and TNF<z mRNA
were determined in the same allergic nasal
mucosa following allergen exposure. This result
suggests a possibility that T cell-derived IFN-7
may take part in up-regulation of TNF<z amplify-
ing sequential allergic events in the allergic nasal
mucosa collaborating with TNF<z derived from
other inflammatory cells such as T cells and mast
cells. Details of cell-to-cell interaction through the
cytokine network relevant to TNF-z remain to be
clarified in nasal allergy.
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